Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Publication year range
1.
Scand J Clin Lab Invest ; 59(3): 191-7, 1999 May.
Article in English | MEDLINE | ID: mdl-10400163

ABSTRACT

Studies on the relative potency of ligands for the epidermal growth factor receptor are usually performed with highly purified ligand specimens. However, adsorption of ligands to glass and plastic surfaces may affect the results by reducing the ligand concentration in an unpredictable way. The aim of this study was to examine the adsorption of four epidermal growth factor (EGF) receptor ligands, EGF, transforming growth factor alpha (TGF-alpha), heparin binding-EGF (HB-EGF) and betacellulin, to commonly used test tubes of polyethylene, polystyrene and glass, respectively. The ligands were kept in a sodium phosphate buffer, both with and without 0.1% human albumin as carrier protein. Adsorption was examined after 20 minutes at room temperature as well as after overnight storage at 4 degrees C. The ligands were quantitated by ELISAs. In the buffer not containing 0.1% human albumin there was a marked adsorption, which differed both among the ligands and among the test tubes. After 20 minutes the ligand concentrations were reduced to 33-73% in polyethylene tubes, to 15-46% in polystyrene tubes and to 12-29% in glass tubes. The adsorption was even more pronounced after storage overnight. The use of 0.1% human albumin in the buffer solved the problem in polyethylene and polystyrene tubes, but not in glass tubes. The results demonstrate that adsorption to surfaces can be a significant problem for EGF receptor ligands and emphasize the need for controlling the growth factor concentration in the final experimental setting.


Subject(s)
Epidermal Growth Factor/pharmacokinetics , ErbB Receptors/metabolism , Glass , Intercellular Signaling Peptides and Proteins , Polyethylenes , Adsorption , Betacellulin , Chemistry, Clinical/standards , Enzyme-Linked Immunosorbent Assay/standards , Epidermal Growth Factor/analysis , Epidermal Growth Factor/pharmacology , Growth Substances/analysis , Growth Substances/pharmacokinetics , Growth Substances/pharmacology , Heparin-binding EGF-like Growth Factor , Humans , Ligands , Polystyrenes , Protein Binding , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Reproducibility of Results , Transforming Growth Factor alpha/analysis , Transforming Growth Factor alpha/pharmacokinetics , Transforming Growth Factor alpha/pharmacology
2.
Mol Pharmacol ; 43(2): 207-16, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8094226

ABSTRACT

Drug resistance to inhibitors of DNA topoisomerase II can result from qualitative or quantitative alterations in the target enzyme, topoisomerase II, or from perturbations in drug transport that may or may not involve P-glycoprotein. In the present study, a drug-resistant Chinese hamster ovary cell line, SMR16, was selected in the presence of an epipodophyllotoxin (VP-16) and was found to be cross-resistant to all classes of topoisomerase II inhibitors (3-35-fold). The 3-fold level of resistance of these cells to vincristine is likely due to diminished uptake of this drug, and this is not mediated by overexpression of P-glycoprotein. No alteration in transport of VP-16 was observed. Immunoblotting with several polyclonal anti-topoisomerase II antibodies demonstrated that the resistant cells contain approximately two-thirds of the parental enzyme amount. The topoisomerase II catalytic activity present in 0.35 M NaCl nuclear extracts paralleled this decrease. VP-16- and 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced DNA damage, mediated by topoisomerase II, was found to be decreased 10-12-fold in both intact SMR16 cells and nuclei isolated from these cells, when measured by alkaline filter elution. However, the VP-16-induced DNA cleavage activity present in 0.35 M NaCl nuclear extracts of the resistant cells was attenuated only 2-fold, relative to wild-type cells. Homogeneous preparations of the enzyme obtained from resistant cells demonstrated the same cleavage and catalytic activity as purified wild-type topoisomerase II. Analysis by pulse-field gel electrophoresis of the DNA isolated from VM-26- and 4'-(9-acridinylamino)methanesulfon-m-anisidide-treated sensitive and resistant cells demonstrated significantly less conversion of SMR16 chromosomal DNA into 50-150-kilobase DNA fragments. Chinese hamster ovary SMR16 cells are apparently resistant to topoisomerase II poisons because the topoisomerase II that defines the DNA topological domains is either decreased in amount or insensitive to drug action.


Subject(s)
Antineoplastic Agents/pharmacology , DNA Topoisomerases, Type II/physiology , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Animals , Antineoplastic Agents/pharmacokinetics , CHO Cells , Catalysis , Cell Division/drug effects , Cricetinae , DNA Damage , Drug Resistance/physiology , Electrophoresis, Gel, Pulsed-Field , Membrane Glycoproteins/physiology , Topoisomerase II Inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL